ST. LOUIS, MO--(Marketwire - February 16, 2010) -
ISTO Technologies, Inc. announced today that
it will participate in the 2010 Canaccord Adams Musculoskeletal Conference
to be held at the Sheraton New Orleans Hotel on Tuesday, March 9, 2010.
Mitchell Seyedin, Ph.D., President and CEO, is scheduled to provide an
overview of the Company at 8:20 a.m. Central Time. The conference,
directly preceding the 2010 American Academy of Orthopedic Surgeons Annual
Meeting, will showcase a diverse group of public and private companies in
the areas of orthopedics, biologics, dental implants, ENT, imaging, robotic
surgery, tissue sculpting, and regenerative medicine.
ISTO is a privately-held orthobiologics company dedicated to improving
patient quality of life through the development of proprietary products for
spinal therapies and sports medicine applications.
The Company's leading cartilage regeneration product, DeNovo® ET, is a
scaffold-free engineered cartilage tissue derived from expanded juvenile
chondrocytes and is currently in human clinical trials for the repair of
injured knee joints as an investigational product.
ISTO's second cell-based product in development, NuQu™, is an injectable
formulation of juvenile cartilage cells intended for regeneration and
repair of tissue lost to chronic disc diseases. NuQu is intended for
minimally invasive intervention for patients suffering from discogenic back
pain. ISTO has received IND approval from the FDA to commence with a Phase
I clinical trial for NuQu, which is scheduled to start in early 2010.
In addition to ISTO's clinical-stage cell-based cartilage programs, the
company is currently producing and selling, InQu®, an osteobiologic bone
graft extender and substitute. The primary target market for the product
is spinal fusion applications. InQu is a biologic bone grafting material
with integrated hyaluronic acid and a synthetic polymer representing a new
class of biomaterials for better handling and biology.
ISTO Technologies, Inc. is developing and marketing clinical solutions for
sports medicine applications and spinal therapies. ISTO's products are
intended for the repair and regeneration of damaged or injured cartilage,
discs and bone. For additional information on ISTO, please visit our
website at www.istotech.com or contact Scott Gill, Chief Financial Officer,